Maiden Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 03-12-2024
- Paid Up Capital ₹ 5.73 M
as on 03-12-2024
- Company Age 34 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.10 Cr
as on 03-12-2024
- Satisfied Charges ₹ 12.12 Cr
as on 03-12-2024
- Revenue 5.80%
(FY 2022)
- Profit -353.48%
(FY 2022)
- Ebitda 23.51%
(FY 2022)
- Net Worth -7.02%
(FY 2022)
- Total Assets 29.95%
(FY 2022)
About Maiden Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.73 M.
The company currently has active open charges totaling ₹2.10 Cr. The company has closed loans amounting to ₹12.12 Cr, as per Ministry of Corporate Affairs (MCA) records.
Naresh Goyal, Vivek Goyal, and Rakhi serve as directors at the Company.
- CIN/LLPIN
U24230DL1990PLC042161
- Company No.
042161
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Nov 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Maiden Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Goyal  | Director | 15-Dec-2016 | Current |
| Naresh Goyal | Director | 01-Nov-2005 | Current |
| Rakhi | Director | 26-Sep-2022 | Current |
Financial Performance of Maiden Pharmaceuticals.
Maiden Pharmaceuticals Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 5.8% increase. The company also saw a substantial fall in profitability, with a 353.48% decrease in profit. The company's net worth dipped by a decrease of 7.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maiden Pharmaceuticals?
In 2022, Maiden Pharmaceuticals had a promoter holding of 89.11% and a public holding of 10.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 18 Jan 2022 | ₹1.50 Cr | Open |
Others Creation Date: 26 Jul 2021 | ₹6.00 M | Open |
Others Creation Date: 26 Feb 2022 | ₹4.99 Cr | Satisfied |
How Many Employees Work at Maiden Pharmaceuticals?
Unlock and access historical data on people associated with Maiden Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maiden Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maiden Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
